SVB Collapse Could Materially Impact Coinbase’s Revenue, Profitability Considering USDC’s Criticality To Coinbase, Analyst Says
Mizuho analyst Dan Dolev reiterates Underperform rating on Coinbase Global, Inc (NASDAQ: COIN)
Silicon Valley Bank Collapse Might Have Limited Impact On Asia, But Confidence Seems Shaken
Some Asian firms have disclosed cash deposits at troubled U.S. lender Silicon Valley Bank (NASDAQ: SIVB), known for its deep ties with the healthcare and tech sector. Most emphasized that the amounts were immaterial to their operations.
Why Several Bank Stocks Are Getting Rocked Today
Shares of several banks and financial companies are trading lower following the closure of SVB Financial Group (NASDAQ: SIVB) and Signature Bank (NASDAQ: SBNY), which has sparked fears of contag
Insurance Stocks Moving In Monday’s Intraday Session
According to Benzinga Pro following are the gainers and losers in Insurance industry for today’s Intraday session. Gainers…
9 Communication Services Stocks Moving In Monday’s Intraday Session
Gainers AdTheorent Holding (NASDAQ:ADTH) stock moved upwards by 16.7% to $1.61 during Monday’s regular session. AdTheorent Holding’s stock…
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.
Why Silicon Valley Bank Collapsed: A Simple Explainer
Almost everyone has heard by now that one of the biggest banks focused on serving startups and innovative tech companies collapsed in a matter of days, but a lot of things played into its eventual destruction.
Why Rivian Automotive Shares Are Trading Lower Today
Amazon.Com, Inc (NASDAQ: AMZN) and Rivian Automotive, Inc (NASDAQ: RIVN) are in discussions to eliminate the exclusivity part of their electric-van deal.
Provention Bio’s $2.9B Acquisition – A Strategic Fit For Sanofi
Sanofi SA (NASDAQ:SNY) has agreed to acquire Provention Bio Inc (NASDAQ:PRVB) for $25.00 per share in cash, representing an equity value of approximately…
Acadia Pharma’s Rett Syndrome Drug Becomes First FDA-Approved Treatment
The FDA has approved Acadia Pharmaceuticals Inc’s (NASDAQ:ACAD) Daybue (trofinetide) for Rett syndrome in adult and pediatric patients two years of…